We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -3.03% | 0.80 | 511,502 | 10:33:59 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.75 | 0.85 | 0.825 | 0.80 | 0.825 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | -1.03M | -0.0057 | -1.40 | 1.45M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 13:09:44 | O | 10,000 | 0.825 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/4/2024 | 07:00 | UK RNS | N4 Pharma PLC N4 Pharma Webinar on SRI Collaboration |
| 25/4/2024 | 11:56 | ALNC |  N4 Pharma strikes partnership deal for intracellular delivery |
| 25/4/2024 | 07:38 | UK RNS | N4 Pharma PLC Collaboration Agreement with SRI International Inc |
| 23/4/2024 | 13:32 | ALNC | IN BRIEF: N4 Pharma loss widens but "great optimism" remains |
| 23/4/2024 | 07:00 | UK RNS | N4 Pharma PLC Final Results |
| 18/4/2024 | 12:14 | ALNC | N4 Pharma sees potential in Nuvec delivery method for cancer treatment |
| 18/4/2024 | 07:00 | UK RNS | N4 Pharma PLC Oral Delivery Update |
| 04/3/2024 | 15:13 | UK RNS | N4 Pharma PLC Holding(s) in Company |
| 29/2/2024 | 07:00 | UK RNS | N4 Pharma PLC Holding(s) in Company |
| 15/2/2024 | 12:06 | ALNC | IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research |
N4 Pharma (N4P) Share Charts1 Year N4 Pharma Chart |
|
1 Month N4 Pharma Chart |
Intraday N4 Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2024 | 10:43 | N4 Pharma | 4,133 |
| 20/5/2021 | 08:25 | N4 Pharma - Making good drugs better. | 4,391 |
| 14/9/2020 | 07:40 | N4P Covid-19 Wealth Warning | 108 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 12:09:45 | 0.83 | 10,000 | 82.50 | O |
| 09:40:41 | 0.77 | 1,000 | 7.65 | O |
| 09:36:53 | 0.77 | 250,000 | 1,912.50 | O |
| 09:33:39 | 0.77 | 250,000 | 1,912.50 | O |
| 09:33:27 | 0.85 | 150 | 1.28 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by N4 Pharma Daily Update N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.83p.N4 Pharma currently has 181,080,349 shares in issue. The market capitalisation of N4 Pharma is £1,448,643. N4 Pharma has a price to earnings ratio (PE ratio) of -1.40. This morning N4P shares opened at 0.83p |
Posted at 18/4/2024 07:09 by jakleeds 18 April 2024N4 Pharma plc ("N4 Pharma" or the "Company") Oral Delivery Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work. The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads. Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control. Nigel Theobald, Chief Executive Officer of the Company, commented: "This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples. "We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them." For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub |
Posted at 29/2/2024 09:12 by nobbygnome Yes that’s why he has been posting so much; he is trying to ramp the price now he has upped his holding! |
Posted at 28/2/2024 11:31 by nobbygnome I think we need another one of Nigel’s vacuous ‘positive̵ |
Posted at 23/2/2024 07:22 by nobbygnome Pharma/biotech don’t take risks. The chances are they will wait for all the pre clinical work to be completed before they even contemplate a deal. Just imagine the poor guy who advocates signing the deal….and then it fails in a tox study. He will have serious egg on his face and his career will be blighted.N4P is desperate for cash and there really is no rush for Pharma to do a deal. Just wait for the N4P price to slump as another fund raise comes along… |
Posted at 21/2/2024 19:08 by dplewis1 Yes, more dilution to buy it. I hear all the most promising pharma companies are on sale for less than the price of a 1 bedroom flat |
Posted at 19/2/2024 10:47 by nobbygnome I guess I have to apologise to Fydo for being correct over the last 5 or 6 years. Right from the start when I highlighted the issues with the Viagra extended dose form of the drug you slated me but like just about everything else N4P have touched it failed! Ho hum…. |
Posted at 19/2/2024 08:08 by nobbygnome >> featherbyBut understanding the science is critical to knowing whether N4P is a good investment or not!! And although as always I will judge the evidence as it appears, I doubt very much I will ever be buying N4P. I have severe doubts the technology will work in humans… |
Posted at 19/2/2024 07:24 by nobbygnome >> FydoUsing my PhD in immunology and 28 years of experience in the Pharma industry, I comment on the many issues with Nuvec and N4P more generally. If you want to have a debate about the science please go ahead! I remember about 5 years ago after Nigel had a trip to Japan Dave was getting excited about the imminent commercialisation of Nuvec. Here we are in 2024 and it hasn’t even been put in a human yet! |
Posted at 18/2/2024 18:22 by nobbygnome Dave Farrier has been a clueless ramper here for many years as the price has sunk from above 30p. He does deserve to be called out…. |
Posted at 15/2/2024 07:20 by jakleeds 15 February 2024N4 Pharma plc ("N4 Pharma" or the "Company") in-vitro siRNA update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further encouraging update on its ongoing in vitro siRNA research work. The Company has now completed its in-vitro experiments combining EGFR (epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) siRNA molecules onto the same Nuvec® nanoparticle and testing it in PC9 lung cancer cells. The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle. Specifically, when cells were treated with the highest dose of 75nanomolars (nm) of single loaded EGFR siRNA, cell viability after 48 hours dropped to 38%. When cells were treated with 75nm of single loaded PLK1 siRNA cell viability dropped to 33%, yet when 75nm of EGFR and PLK1 were combined together cell viability dropped to 19%. The cellular inhibition effect increases over time up to 48 hours and increases with the amount of siRNA applied. The experiments were carried out a number of times showing a consistent effect. The Company will now expand this work by testing knockdown of EGFR alongside BRD4 (Bromodomain-contain Nigel Theobald, Chief Executive Officer of the Company, commented: "The work we are doing on multiple loading of siRNA onto one nanoparticle is extremely encouraging and is showcasing the versatility of our Nuvec® delivery system. "This ability to be able to knockdown two independent pathways leading to a positive added impact is an innovative approach in developing novel cancer treatments aimed at reducing the ability for tumour escape. We will continue to present this data to potential licensing partners as all this work strengthens the potential for collaboration opportunities." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
